RBMS2 Chemosensitizes Breast Cancer Cells to Doxorubicin by Regulating BMF Expression

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Chemoresistance significantly impacts breast cancer treatment outcomes and patient prognosis.
• RNA binding proteins (RBPs) are increasingly recognized for their roles in cancer progression and response to chemotherapy.
• The specific function of RNA binding motif single stranded interacting protein 2 (RBMS2) in doxorubicin sensitivity in breast cancer remains largely undefined.

Purpose of the Study:

• To investigate the role of RBMS2 in modulating doxorubicin sensitivity in breast cancer.
• To elucidate the underlying molecular mechanisms by which RBMS2 influences chemoresistance.
• To explore RBMS2 as a potential therapeutic target for overcoming doxorubicin resistance in breast cancer.

Main Methods:

• In vitro and in vivo experiments including doxorubicin cytotoxicity assays, flow cytometry, and mouse xenograft models.
• RNA immunoprecipitation (RIP) assay to assess the interaction between RBMS2 and BMF.
• Dual-luciferase reporter assay to confirm the regulatory relationship between RBMS2 and BMF.

Main Results:

• Upregulation of RBMS2 increased breast cancer cell sensitivity to doxorubicin and promoted apoptosis.
• Inhibition of RBMS2 led to decreased doxorubicin sensitivity and reduced apoptosis.
• The chemosensitizing effect of RBMS2 was dependent on Bcl-2 modifying factor (BMF) expression, with RBMS2 positively regulating BMF and downstream apoptosis markers (caspase 3, caspase 9, PARP).

Conclusions:

• RBMS2 enhances doxorubicin sensitivity in breast cancer by positively regulating BMF expression, thereby promoting apoptosis.
• This study reveals a novel mechanism involving RBMS2 and BMF in chemoresistance.
• RBMS2 represents a promising therapeutic target for improving the efficacy of doxorubicin treatment in drug-resistant breast cancer.